Recent Material Events - Sciclone Pharmaceutical (SCLN)

Filing Date	Description
2008-07-29	On July 29, 2008, SciClone Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2008. A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorpor ...
2008-05-30	On May 23, 2008, SciClone Pharmaceuticals International Limited, a 100% subsidiary of SciClone Pharmaceuticals, Inc. (collectively, the "Company"), executed a Manufacturing Supply Agreement, dated as of December 31, 2006, with Lonza Sales Limited (t ...
2008-05-09	On May 8, 2008, SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”) entered into a Change in Control Agreement with Ivan Hui, Assistant Vice President, Finance (the “Change in Control Agreement”). Pursuant t ...
2008-05-08	On May 8, 2008, SciClone Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2008. A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorporat ...
2008-04-07	On April 4, 2008, SciClone Pharmaceuticals, Inc. (the "Company") announced that Richard Waldron has resigned, effective as of April 30, 2008, as Executive Vice President and Chief Financial Officer and an employee of the Company. ...
2008-03-21	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ...
2008-03-13	On March 13, 2008, SciClone Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2007. A copy of the Company's press release is attached hereto as Exhibit 99. ...
2008-02-25	On February 21, 2008, SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”) entered into a Change in Control Agreement with Cynthia Tuthill, Ph.D., Senior Vice President, Scientific Affairs and Chief Scientific Officer (t ...
2007-12-21	(a) On December 17, 2007, the Board of Directors of SciClone Pharmaceuticals, Inc. (the “Company”) adopted amendments to Article IV, Sections 4.2, 4.3 and 4.4 of the Company’s Bylaws (the “Restated Bylaws”), effective ...
2007-09-14	As permitted in the previously-disclosed Rights Agreement dated as of December 19, 2006 between SciClone Pharmaceuticals, Inc. (the “Company”) and Mellon Investor Services LLC (the “Rights Agreement”), on September 10, 200 ...